
|Articles|May 13, 2004
Drug treats PCa patients with bone metastases
Novartis offers zoledronic acid injection (ZOMETA) for the treatmentof patients with documented bone metastases from solid tumors, includingprostate cancer, in conjunction with standard antineoplastic therapy.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Urologist describes early experience with gemcitabine intravesical system in NMIBC
2
Ronney Abaza, MD, discusses the next wave of advancements in robotic surgery
3
Ravi Chauhan, MD, discusses integrating nadofaragene into clinical practice
4
Joshua J. Meeks, MD, PhD, highlights dosing schedule advantage of nadofaragene in NMIBC
5



















